11,000 Shares in United Therapeutics Corporation $UTHR Acquired by Elmind Capital LP

Elmind Capital LP purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,000 shares of the biotechnology company’s stock, valued at approximately $5,360,000. United Therapeutics makes up 1.6% of Elmind Capital LP’s investment portfolio, making the stock its 18th biggest position.

Other large investors have also recently made changes to their positions in the company. Torren Management LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB increased its position in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $48,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,712,246.04. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $549.15, for a total value of $5,216,925.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,247,713.95. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 636,168 shares of company stock valued at $359,249,237 in the last three months. 8.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on UTHR shares. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Bank of America boosted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Up 0.6%

Shares of UTHR opened at $551.47 on Thursday. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market capitalization of $23.41 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. The stock has a fifty day simple moving average of $565.95 and a two-hundred day simple moving average of $522.96.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the business earned $6.63 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.